Critical reviews in oncology/hematology最新文献

{"title":"The influence of genetic variation on late effects in childhood cancer survivors: An updated systematic review","authors":"Melissa Bolier ,&nbsp;Stefanie J.M. van Leerdam ,&nbsp;Linda Broer ,&nbsp;Anne-Lotte F. van der Kooi ,&nbsp;Amirhossein Masroor ,&nbsp;Merel W. van Gijzen ,&nbsp;Nienke Streefkerk ,&nbsp;Francis S.P. Wens ,&nbsp;Demi T.C. de Winter ,&nbsp;Oliver Zolk ,&nbsp;Marieke J.H. Coenen ,&nbsp;Carmen L. Wilson ,&nbsp;Melissa M. Hudson ,&nbsp;Sebastian J.C.M.M. Neggers ,&nbsp;Marry M. van den Heuvel-Eibrink","doi":"10.1016/j.critrevonc.2025.104977","DOIUrl":"10.1016/j.critrevonc.2025.104977","url":null,"abstract":"<div><h3>Introduction</h3><div>Variation in the prevalence and severity of late effects in similarly treated childhood cancer survivors suggests a role for genetic susceptibility. We aimed to provide an overview of genetic factors associated with selected late effects after childhood cancer, including metabolic syndrome, gonadal insufficiency, hearing impairment, and musculoskeletal impairment.</div></div><div><h3>Methods</h3><div>A systematic literature search in Medline, Embase, Web of Science, and Cochrane was performed in April 2025. Articles describing ≥ 50 survivors diagnosed with cancer ≤ 21 years of age and reporting on genetic variants associated with one of the selected late effects (present after the end of treatment and onwards) were included.</div></div><div><h3>Results</h3><div>From the 4609 unique articles, 60 articles were included (n = 12 on metabolic syndrome (or its components), n = 7 on gonadal insufficiency, n = 26 on hearing impairment, n = 12 on musculoskeletal impairment). Eighty-five variants were significantly associated with one of the selected late effects by ≥ 1 study. One out of twenty variants studied in multiple candidate gene investigations remained significant in meta-analysis (rs4646316/<em>COMT</em>). Five out of six studies including a polygenic risk score showed improved performance when genetic factors were added to clinical models. There was a high heterogeneity in the quality of reporting according to the STREGA tool.</div></div><div><h3>Conclusion</h3><div>Substantial uncertainty remains within the evidence of genetic factors for the selected late effects after childhood cancer. International collaborations, methodological and reporting harmonization, and prioritization of replication and functional validation should help future research to be more consistent, create more robust findings, and bridge the gap between research and clinical practice.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104977"},"PeriodicalIF":5.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis","authors":"Zhihan Chen ,&nbsp;Wenjng Luo ,&nbsp;Yun Kang ,&nbsp;Jia Xu ,&nbsp;Chenggong Li ,&nbsp;Xindi Wang ,&nbsp;Yinqiang Zhang ,&nbsp;Qiaolin Liu ,&nbsp;Heng Mei","doi":"10.1016/j.critrevonc.2025.104969","DOIUrl":"10.1016/j.critrevonc.2025.104969","url":null,"abstract":"<div><h3>Background</h3><div>Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape of patients with hematologic malignancies. Nevertheless, geographic regions may lead to various outcomes, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), overall response rate (ORR), and complete response rate (CRR). However, the related evidence of real-world studies and systematic analysis remains limited.</div></div><div><h3>Objective</h3><div>This meta-analysis aims to compare the real-world incidence of CRS and ICANS, as well as therapeutic outcomes ORR/CRR, in patients with hematologic malignancy treated with CAR-T therapy across different regions.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted in Pubmed, Embase, and Cochrane Library databases published up to February 2025. Subgroup analyses were performed based on geographic regions and other factors.</div></div><div><h3>Results</h3><div>Seventy corhorts from 4 different regions comprising 9233 patients were included. North America exhibited the highest incidence of CRS at 83 %, surpassing Europe (82 %) and Asia (80 %) significantly (p &lt; 0.01). However, no significant regional differences existed in grade ≥ 3 CRS. The incidence of ICANS was notably higher in North America (39 %) compared to Europe (32 %) and Asia (21 %; p = 0.08), with grade ≥ 3 ICANS also more prevalent in North America (16 %) than in Europe (9 %) and Asia (2 %; p &lt; 0.01). Efficacy did not vary across different regions.</div></div><div><h3>Conclusion</h3><div>Patients in North America possessing elevated rates of CRS and grade ≥ 3 ICANS. The results provide valuable insights to the adverse effects when treating patients with CAR-T therapy across different regions in a real-world setting.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104969"},"PeriodicalIF":5.6,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145263574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity","authors":"Yiming Wang ,&nbsp;Xi Cheng ,&nbsp;Xuan Li ,&nbsp;Weijia Chen ,&nbsp;Xiaotao Zhang ,&nbsp;Yanhao Liu","doi":"10.1016/j.critrevonc.2025.104979","DOIUrl":"10.1016/j.critrevonc.2025.104979","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) represent a transformative advancement in targeted cancer therapy by combining monoclonal antibodies with cytotoxic payloads. A critical yet underexplored feature of ADCs is the bystander effect, wherein released payloads diffuse into neighboring cells regardless of target antigen expression. This review synthesizes current understanding of the mechanisms, clinical implications, and optimization strategies related to this phenomenon. Mechanistically, cleavable linkers, hydrophobic payloads, and internalization are critical for bystander activity. However, the characteristics of the tumor microenvironment—elevated interstitial fluid pressure, binding site barrier (BSB), and hypoxia—restrict ADC penetration. Clinically, ADCs with bystander effects (e.g., trastuzumab deruxtecan), demonstrate superior efficacy compared to non-bystander ADCs (e.g., trastuzumab emtansine). Despite these advantages, bystander effect raises concerns regarding off-target toxicity and variable efficacy depending on antigen expression. For instance, while the bystander effect allows payloads to penetrate BSB and increase the killing range, non-bystander ADCs like ARX788 may offer comparable efficacy with reduced toxicity in homogeneous settings. Current insights highlight the need to balance bystander potency with target specificity, particularly in tumors with low antigen density or heterogeneous spatial distribution. Future research should focus on three key areas: (1) quantifying bystander contributions in vivo; (2) clarifying spatiotemporal regulation of payload diffusion by TME factors such as hypoxia and binding-site barriers; and (3) validating combinatorial strategies, including Fc engineering, internalization induction, and TME remodeling, to maximize therapeutic indices. Bridging these gaps will refine ADC design paradigms, aligning with precision oncology’s goal of optimizing efficacy while minimizing systemic toxicity.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104979"},"PeriodicalIF":5.6,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant immunotherapy in high-risk renal cell carcinoma: Indications, limitations, and perspectives. A consensus statement from the GIOTTO uro-oncology group","authors":"Giandomenico Roviello ,&nbsp;Federico Paolieri ,&nbsp;Martina Catalano ,&nbsp;Luca Galli ,&nbsp;Laura Doni ,&nbsp;Federico Peschiera ,&nbsp;Alessandro Pili ,&nbsp;Michele Sisani ,&nbsp;Bloise Francesco","doi":"10.1016/j.critrevonc.2025.104978","DOIUrl":"10.1016/j.critrevonc.2025.104978","url":null,"abstract":"<div><div>Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40 % of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104978"},"PeriodicalIF":5.6,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis","authors":"Francisco Cezar Aquino de Moraes ,&nbsp;Luis Henrique Rios Moreira Rego ,&nbsp;Felipe Alves de Paiva ,&nbsp;Gustavo Tadeu Freitas Uchôa Matheus ,&nbsp;Rommel Mario Rodríguez Burbano","doi":"10.1016/j.critrevonc.2025.104975","DOIUrl":"10.1016/j.critrevonc.2025.104975","url":null,"abstract":"<div><h3>Background</h3><div>Gastric and gastroesophageal junction (GEJ) cancers with HER2 overexpression have limited durable responses to standard HER2-targeted therapies. Adding immune checkpoint inhibitors (ICIs) to anti-HER2 regimens has emerged as a promising strategy to enhance treatment efficacy. This study assessed the efficacy and safety of combining ICIs with trastuzumab therapy in patients with HER2-positive gastric or GEJ adenocarcinoma.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis was conducted according to PRISMA guidelines. Eligible studies included patients with HER2-positive gastric or GEJ cancer treated with chemotherapy inhibitors plus trastuzumab therapy, with or without PD-1/PD-L1. Statistical analyses were performed using the “meta” and “IPDfromKM” packages in R version 4.4.2.</div></div><div><h3>Results</h3><div>From 1306 records, five studies involving 993 patients were included. Combination therapy significantly improved OS (HR, 0.73; 95 % CI, 0.64–0.84; p &lt; .0001); PFS (HR, 0.69; 95 % CI, 0.60–0.80; p &lt; .0001); ORR (OR, 1.95; p &lt; .0001) and DCR (OR, 2.94; p = .009) also favored combination therapy. In the combination therapy, although with insignificant results, patients with CPS≥ 1 showed a tendency to better OS (HR: 0.88; 95 % CI, 0.52–1.49; p = .58) and PFS (HR: 0.82; 95 % CI, 0.48–1.42; p = 0.4). Hypothyroidism was more frequent with combination therapy (RR, 3.24; p = .008), while other 11 AEs showed no difference between groups.</div></div><div><h3>Conclusions</h3><div>ICIs plus trastuzumab therapy improve survival and response in advanced HER2-positive gastric or GEJ cancer, particularly in PD-L1–positive and first-line settings, with manageable toxicity.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104975"},"PeriodicalIF":5.6,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145218060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives","authors":"Peng-Fei Zhang ,&nbsp;Xiao-Cui Ye ,&nbsp;Xuan-Qiong Shi ,&nbsp;Ling-Xuan Fu ,&nbsp;Zhi-Han Yang","doi":"10.1016/j.critrevonc.2025.104976","DOIUrl":"10.1016/j.critrevonc.2025.104976","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) have achieved significant success in cancer treatment, yet their associated adverse effects, particularly ICI-related thrombocytopenia (irTCP), are gaining increasing attention. IrTCP leads to serious complications, which affect treatment outcomes and quality of life. Clinical manifestations of irTCP may vary from mild to severe, necessitating careful monitoring during ICIs therapy. To date, several immune-mediated mechanisms, including the destruction of platelets and bone marrow suppression, have been revealed to play crucial roles in the pathogenesis of irTCP. Despite advancements in understanding these mechanisms, challenges remain in the timely diagnosis and effective management of irTCP. In this review, we synthesize the latest findings in the field and elucidate the mechanisms, clinical manifestations, diagnostic approaches, and management strategies of irTCP, aiming to provide insights for clinical practice and future research directions.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104976"},"PeriodicalIF":5.6,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and chemoradiotherapy response in rectal cancer: Biomarker opportunities","authors":"Christophe Taoum ,&nbsp;Amandine Devaux ,&nbsp;Philippe Rouanet ,&nbsp;Pierre-Emmanuel Colombo ,&nbsp;Delphine Boucher ,&nbsp;Mathilde Bonnet","doi":"10.1016/j.critrevonc.2025.104974","DOIUrl":"10.1016/j.critrevonc.2025.104974","url":null,"abstract":"<div><div>The gut microbiota is increasingly recognized as a key factor in rectal carcinogenesis. This review synthesizes current clinical and preclinical evidence linking specific microbial signatures, such as <em>Fusobacterium nucleatum</em>, <em>Duodenibacillus massiliensis</em> and colibactin-producing <em>Escherichia coli</em> (CoPEC) to chemoradiotherapy (CRT) treatment efficacy and resistance. Microbiota-driven mechanisms include immune modulation, inflammation, and drug metabolism. We highlight emerging microbial biomarkers and therapeutic strategies such as antibiotics, probiotics, and fecal microbiota transplantation. Integrating microbiome profiling into clinical workflows could refine patient stratification and enhance CRT efficacy in rectal cancer. Ongoing clinical trials aim to validate these associations and establish robust microbial biomarkers for CRT response prediction in rectal cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104974"},"PeriodicalIF":5.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could immune checkpoints PD-1/PD-L1, PD-L2 and CTLA-4 be valuable in the spontaneous canine model of breast cancer?","authors":"Marta Monteiro ,&nbsp;Marta Santos ,&nbsp;Andreia Santos","doi":"10.1016/j.critrevonc.2025.104973","DOIUrl":"10.1016/j.critrevonc.2025.104973","url":null,"abstract":"<div><div>Immunotherapy has emerged as an auspicious new therapeutic modality in oncology, with immune checkpoint inhibitors showing promising results on several malignancies. Immune checkpoint molecules, such as PD-1 and its ligands (PD-L1 and PD-L2) and CTLA-4 represent a physiological mechanism to downregulate immune activity. This pathway seems to be used by different tumors to evade immune system and suppressing tumor-specific immune responses. Immune checkpoints expression in some tumors is related to higher malignancy and poor prognosis. The association of immune checkpoints with worst outcome has also been established specifically in human breast cancer. The evaluation of the role of immune checkpoints in canine mammary tumors is still very incipient. Therefore, further research will be needed in this field in order to provide new treatment and diagnosis targets and predictive factors with potential benefit for both human and animals. Herein, we provide an updated narrative review of the role of immune checkpoints in canine mammary tumors in comparison with breast cancer, emphasizing recent advances and the translational relevance of these pathways in comparative oncology.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104973"},"PeriodicalIF":5.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From innate power to intelligent design: The evolution of NK cell-based cancer immunotherapy","authors":"Israth Jahan Tuhin ,&nbsp;Hong Jia Zhu ,&nbsp;Masuma Akter Monty ,&nbsp;Jin Wen Tan ,&nbsp;Nan Xu ,&nbsp;Jing Ye ,&nbsp;Lei Yu","doi":"10.1016/j.critrevonc.2025.104972","DOIUrl":"10.1016/j.critrevonc.2025.104972","url":null,"abstract":"<div><div>Natural killer (NK) cells have emerged as a promising platform for cancer immunotherapy due to their intrinsic cytotoxicity, lack of antigen restriction, and minimal risk of graft-versus-host disease, enabling the development of safe and scalable “off-the-shelf” therapies. However, their clinical efficacy, particularly in solid tumors, remains limited by poor in vivo persistence, inadequate tumor infiltration, and suppression by the immunosuppressive tumor microenvironment (TME). This review highlights the recent advances in genetic engineering strategies to enhance NK cell antitumor function. We discuss the optimization of chimeric antigen receptors (CARs) specifically for NK cells, the integration of immune checkpoint resistance, metabolic reprogramming, and the incorporation of cytokine support to improve survival and potency. In parallel, we explore combination strategies that synergize with NK cells, including monoclonal antibodies, oncolytic viruses, vaccines, and adoptive immune cell therapy. Additionally, we examine innovative platforms such as nanoparticle delivery systems and NK cell-derived exosomes to further enhance therapeutic outcomes. By systematically addressing the intrinsic and extrinsic limitations of NK cells through genetic precision and combinatorial immunomodulation, NK-based therapies are poised to transition from supportive to frontline modalities in cancer treatment. This review provides a comprehensive roadmap for the next generation of NK cell therapies with broad translational potential.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104972"},"PeriodicalIF":5.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of GPI-anchored LY6/uPAR family proteins in connecting membrane microdomains with immune regulation and diseases","authors":"Jingyi Wen ,&nbsp;Le Wu ,&nbsp;Shangwei Zhong ,&nbsp;Hanguo Shan ,&nbsp;Jun-Li Luo","doi":"10.1016/j.critrevonc.2025.104971","DOIUrl":"10.1016/j.critrevonc.2025.104971","url":null,"abstract":"<div><div>Glycosylphosphatidylinositol (GPI)-anchored LY6/uPAR family proteins are structurally conserved yet functionally diverse regulators of immune signaling. Defined by a characteristic three-finger LY6/uPAR (LU) domain and preferential localization to lipid rafts, members such as LY6A, LY6C, LY6E, LY6G, CD59, PSCA, and uPAR orchestrate essential immune processes, including T and B cell activation, dendritic cell maturation, neutrophil and natural killer (NK) cell responses, and macrophage polarization. These proteins are increasingly implicated in the pathogenesis of cancer, infectious diseases, autoimmune disorders, and neuroinflammation. GPI anchoring facilitates receptor pre-orientation, nanocluster formation, and rapid signal transduction within membrane microdomains, thereby enabling precise spatial and temporal control of immune signaling. Several LY6/uPAR members have emerged as promising clinical targets, with translational strategies encompassing CAR-T cell therapies, antibody–drug conjugates, and lipid raft–modulating agents. This review presents a comprehensive overview of current knowledge, linking the structural, spatial, and functional characteristics of LY6/uPAR proteins to their relevance in health and disease, identifying key unresolved mechanistic questions, and underscoring emerging translational opportunities within the context of precision immunology.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"216 ","pages":"Article 104971"},"PeriodicalIF":5.6,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}